In general, the proposed mechanism explaining the action of SGLT-2 inhibitors in NAFLD/NASH is based on the reduction of plasma glucose due to glucosuria, and reversal of glucotoxicity, as well as reductions in circulating insulin and body weight. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.